NATCO Pharma Limited (BSE: NATCOPHARM.BO) Stock Competitors & Peer Comparison

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUNPHARMA.NS has a market cap of 4.6T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUNPHARMA.NS trades at ₹1,902.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUNPHARMA.NS's P/E ratio is 36.95. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUNPHARMA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUNPHARMA.BO has a market cap of 4.6T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUNPHARMA.BO trades at ₹1,900.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUNPHARMA.BO's P/E ratio is 37.27. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUNPHARMA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, DIVISLAB.NS has a market cap of 2.3T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while DIVISLAB.NS trades at ₹8,597.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas DIVISLAB.NS's P/E ratio is 78.05. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DIVISLAB.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, DIVISLAB.BO has a market cap of 2.3T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while DIVISLAB.BO trades at ₹8,550.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas DIVISLAB.BO's P/E ratio is 77.59. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DIVISLAB.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, TORNTPHARM.BO has a market cap of 1.9T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while TORNTPHARM.BO trades at ₹4,880.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas TORNTPHARM.BO's P/E ratio is 74.06. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check TORNTPHARM.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, TORNTPHARM.NS has a market cap of 1.9T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while TORNTPHARM.NS trades at ₹4,896.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas TORNTPHARM.NS's P/E ratio is 73.37. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check TORNTPHARM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, CIPLA.BO has a market cap of 1.2T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while CIPLA.BO trades at ₹1,426.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas CIPLA.BO's P/E ratio is 29.95. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CIPLA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, CIPLA.NS has a market cap of 1.2T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while CIPLA.NS trades at ₹1,432.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas CIPLA.NS's P/E ratio is 34.49. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CIPLA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ZYDUSLIFE.BO trades at ₹1,120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ZYDUSLIFE.BO's P/E ratio is 26.38. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ZYDUSLIFE.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ZYDUSLIFE.NS trades at ₹1,120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ZYDUSLIFE.NS's P/E ratio is 26.22. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ZYDUSLIFE.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while LUPIN.NS trades at ₹2,201.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas LUPIN.NS's P/E ratio is 17.29. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LUPIN.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while LUPIN.BO trades at ₹2,193.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas LUPIN.BO's P/E ratio is 17.21. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LUPIN.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, DRREDDY.BO has a market cap of 987.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while DRREDDY.BO trades at ₹1,175.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas DRREDDY.BO's P/E ratio is 22.85. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DRREDDY.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, MANKIND.NS has a market cap of 984.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while MANKIND.NS trades at ₹2,384.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas MANKIND.NS's P/E ratio is 45.61. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MANKIND.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, LAURUSLABS.BO has a market cap of 979.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while LAURUSLABS.BO trades at ₹1,814.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas LAURUSLABS.BO's P/E ratio is 89.35. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LAURUSLABS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, MANKIND.BO has a market cap of 979.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while MANKIND.BO trades at ₹2,372.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas MANKIND.BO's P/E ratio is 45.37. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MANKIND.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, DRREDDY.NS has a market cap of 978.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while DRREDDY.NS trades at ₹1,174.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas DRREDDY.NS's P/E ratio is 29.58. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check DRREDDY.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, LAURUSLABS.NS has a market cap of 973.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while LAURUSLABS.NS trades at ₹1,802.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas LAURUSLABS.NS's P/E ratio is 88.94. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check LAURUSLABS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AUROPHARMA.NS has a market cap of 932.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AUROPHARMA.NS trades at ₹1,621.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AUROPHARMA.NS's P/E ratio is 25.33. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AUROPHARMA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AUROPHARMA.BO has a market cap of 931.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AUROPHARMA.BO trades at ₹1,619.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AUROPHARMA.BO's P/E ratio is 25.31. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AUROPHARMA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLENMARK.BO has a market cap of 666.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLENMARK.BO trades at ₹2,306.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLENMARK.BO's P/E ratio is 36.21. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLENMARK.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLENMARK.NS has a market cap of 654.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLENMARK.NS trades at ₹2,317.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLENMARK.NS's P/E ratio is 37.99. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLENMARK.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ALKEM.NS has a market cap of 645.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ALKEM.NS trades at ₹5,400.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ALKEM.NS's P/E ratio is 29.89. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALKEM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ALKEM.BO has a market cap of 644.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ALKEM.BO trades at ₹5,397.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ALKEM.BO's P/E ratio is 29.91. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALKEM.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, IPCALAB.BO has a market cap of 488.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while IPCALAB.BO trades at ₹1,910.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas IPCALAB.BO's P/E ratio is 36.09. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IPCALAB.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, IPCALAB.NS has a market cap of 484.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while IPCALAB.NS trades at ₹1,911.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas IPCALAB.NS's P/E ratio is 35.90. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IPCALAB.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLAND.NS has a market cap of 465.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLAND.NS trades at ₹2,819.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLAND.NS's P/E ratio is 41.12. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLAND.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLAND.BO has a market cap of 465B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLAND.BO trades at ₹2,820.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLAND.BO's P/E ratio is 41.15. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLAND.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLAND.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AJANTPHARM.NS has a market cap of 454.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AJANTPHARM.NS trades at ₹3,639.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AJANTPHARM.NS's P/E ratio is 40.12. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AJANTPHARM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AJANTPHARM.BO has a market cap of 454.2B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AJANTPHARM.BO trades at ₹3,640.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AJANTPHARM.BO's P/E ratio is 40.12. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.BO is similarly volatile compared to AJANTPHARM.BO. This indicates similar risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AJANTPHARM.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVENPHAR.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVENPHAR.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JBCHEPHARM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, EMCURE.NS has a market cap of 353.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while EMCURE.NS trades at ₹1,863.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas EMCURE.NS's P/E ratio is 34.06. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check EMCURE.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, NEULANDLAB.BO has a market cap of 299.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while NEULANDLAB.BO trades at ₹23,294.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas NEULANDLAB.BO's P/E ratio is 59.22. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NEULANDLAB.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, NEULANDLAB.NS has a market cap of 298.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while NEULANDLAB.NS trades at ₹23,301.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas NEULANDLAB.NS's P/E ratio is 59.07. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NEULANDLAB.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, PPLPHARMA.NS has a market cap of 283.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while PPLPHARMA.NS trades at ₹213.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas PPLPHARMA.NS's P/E ratio is -182.45. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PPLPHARMA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, PPLPHARMA.BO has a market cap of 282.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while PPLPHARMA.BO trades at ₹213.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas PPLPHARMA.BO's P/E ratio is -182.35. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PPLPHARMA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PEL.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GRANULES.BO has a market cap of 213.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GRANULES.BO trades at ₹858.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GRANULES.BO's P/E ratio is 32.83. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GRANULES.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GRANULES.NS has a market cap of 212.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GRANULES.NS trades at ₹858.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GRANULES.NS's P/E ratio is 32.60. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.BO is similarly volatile compared to GRANULES.NS. This indicates similar risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GRANULES.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, CAPLIPOINT.BO has a market cap of 192.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while CAPLIPOINT.BO trades at ₹2,563.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas CAPLIPOINT.BO's P/E ratio is 29.73. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPLIPOINT.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, CAPLIPOINT.NS has a market cap of 192.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while CAPLIPOINT.NS trades at ₹2,560.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas CAPLIPOINT.NS's P/E ratio is 29.73. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPLIPOINT.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ASTRAZEN.NS has a market cap of 185.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ASTRAZEN.NS trades at ₹7,415.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ASTRAZEN.NS's P/E ratio is 98.86. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ASTRAZEN.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ASTRAZEN.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ASTRAZEN.BO has a market cap of 185.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ASTRAZEN.BO trades at ₹7,410.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ASTRAZEN.BO's P/E ratio is 98.79. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ASTRAZEN.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ASTRAZEN.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ERIS.NS has a market cap of 184.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ERIS.NS trades at ₹1,328.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ERIS.NS's P/E ratio is 37.57. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is similarly volatile compared to ERIS.NS. This indicates similar risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ERIS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ERIS.BO has a market cap of 183.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ERIS.BO trades at ₹1,325.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ERIS.BO's P/E ratio is 42.98. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ERIS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, COHANCE.NS has a market cap of 181.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while COHANCE.NS trades at ₹463.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas COHANCE.NS's P/E ratio is 143.81. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check COHANCE.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, COHANCE.BO has a market cap of 181.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while COHANCE.BO trades at ₹462.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas COHANCE.BO's P/E ratio is 150.25. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check COHANCE.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ALIVUS.NS has a market cap of 165.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ALIVUS.NS trades at ₹1,350.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ALIVUS.NS's P/E ratio is 26.78. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALIVUS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ALIVUS.BO has a market cap of 165.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ALIVUS.BO trades at ₹1,348.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ALIVUS.BO's P/E ratio is 30.00. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ALIVUS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, APLLTD.NS has a market cap of 161.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while APLLTD.NS trades at ₹821.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas APLLTD.NS's P/E ratio is 21.51. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check APLLTD.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, APLLTD.BO has a market cap of 161.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while APLLTD.BO trades at ₹820.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas APLLTD.BO's P/E ratio is 21.48. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check APLLTD.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SHILPAMED.NS has a market cap of 159.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SHILPAMED.NS trades at ₹814.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SHILPAMED.NS's P/E ratio is 51.78. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SHILPAMED.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SHILPAMED.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, NATCOPHARM.NS has a market cap of 158B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while NATCOPHARM.NS trades at ₹882.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas NATCOPHARM.NS's P/E ratio is 13.80. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NATCOPHARM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, JUBLPHARMA.NS has a market cap of 139.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while JUBLPHARMA.NS trades at ₹880.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas JUBLPHARMA.NS's P/E ratio is 36.48. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JUBLPHARMA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, JUBLPHARMA.BO has a market cap of 139.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while JUBLPHARMA.BO trades at ₹879.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas JUBLPHARMA.BO's P/E ratio is 36.48. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to JUBLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check JUBLPHARMA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GLS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUDEEPPHRM.NS has a market cap of 125.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUDEEPPHRM.NS trades at ₹1,111.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUDEEPPHRM.NS's P/E ratio is 128.53. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUDEEPPHRM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, VIYASH.NS has a market cap of 120.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while VIYASH.NS trades at ₹275.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas VIYASH.NS's P/E ratio is 66.33. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check VIYASH.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AKUMS.NS has a market cap of 114.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AKUMS.NS trades at ₹750.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AKUMS.NS's P/E ratio is 39.70. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AKUMS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check CAPPL.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, PGHL.BO has a market cap of 97B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while PGHL.BO trades at ₹5,834.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas PGHL.BO's P/E ratio is 29.64. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PGHL.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, PGHL.NS has a market cap of 96.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while PGHL.NS trades at ₹5,828.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas PGHL.NS's P/E ratio is 29.61. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check PGHL.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, STAR.NS has a market cap of 90.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while STAR.NS trades at ₹986.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas STAR.NS's P/E ratio is 14.83. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check STAR.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, STAR.BO has a market cap of 90.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while STAR.BO trades at ₹985.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas STAR.BO's P/E ratio is 14.83. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to STAR.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check STAR.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUVEN.NS has a market cap of 85.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUVEN.NS trades at ₹373.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUVEN.NS's P/E ratio is -30.94. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVEN.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SUVEN.BO has a market cap of 83.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SUVEN.BO trades at ₹372.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SUVEN.BO's P/E ratio is -30.01. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SUVEN.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SHILPAMED.BO has a market cap of 79.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SHILPAMED.BO trades at ₹814.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SHILPAMED.BO's P/E ratio is 53.44. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SHILPAMED.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AARTIPHARM.NS has a market cap of 74.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AARTIPHARM.NS trades at ₹816.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AARTIPHARM.NS's P/E ratio is 28.23. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIPHARM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AARTIPHARM.BO has a market cap of 73.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AARTIPHARM.BO trades at ₹816.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AARTIPHARM.BO's P/E ratio is 39.41. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIPHARM.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SPARC.NS has a market cap of 63.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SPARC.NS trades at ₹196.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SPARC.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SPARC.BO has a market cap of 63.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SPARC.BO trades at ₹196.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SPARC.BO's P/E ratio is 4.11. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SPARC.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, INNOVACAP.NS has a market cap of 62.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while INNOVACAP.NS trades at ₹1,088.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas INNOVACAP.NS's P/E ratio is 51.18. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check INNOVACAP.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, BLISSGVS.BO has a market cap of 62.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while BLISSGVS.BO trades at ₹582.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas BLISSGVS.BO's P/E ratio is 48.32. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check BLISSGVS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, BLISSGVS.NS has a market cap of 61.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while BLISSGVS.NS trades at ₹579.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas BLISSGVS.NS's P/E ratio is 48.06. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check BLISSGVS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, FDC.NS has a market cap of 56.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while FDC.NS trades at ₹348.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas FDC.NS's P/E ratio is 20.16. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check FDC.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, FDC.BO has a market cap of 56.7B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while FDC.BO trades at ₹348.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas FDC.BO's P/E ratio is 20.14. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to FDC.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check FDC.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, MOREPENLAB.BO has a market cap of 52.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while MOREPENLAB.BO trades at ₹96.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas MOREPENLAB.BO's P/E ratio is 55.49. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MOREPENLAB.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, MOREPENLAB.NS has a market cap of 52.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while MOREPENLAB.NS trades at ₹96.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas MOREPENLAB.NS's P/E ratio is 55.50. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check MOREPENLAB.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ORCHPHARMA.NS has a market cap of 50.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ORCHPHARMA.NS trades at ₹1,002.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ORCHPHARMA.NS's P/E ratio is 161.62. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ORCHPHARMA.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SEQUENT.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check SEQUENT.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, ORCHPHARMA.BO has a market cap of 50.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while ORCHPHARMA.BO trades at ₹997.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas ORCHPHARMA.BO's P/E ratio is 77.68. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check ORCHPHARMA.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, IOLCP.BO has a market cap of 49.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while IOLCP.BO trades at ₹169.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas IOLCP.BO's P/E ratio is 33.25. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IOLCP.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, IOLCP.NS has a market cap of 49.8B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while IOLCP.NS trades at ₹169.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas IOLCP.NS's P/E ratio is 33.37. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check IOLCP.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, RPGLIFE.BO has a market cap of 43.9B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while RPGLIFE.BO trades at ₹2,634.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas RPGLIFE.BO's P/E ratio is 37.83. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check RPGLIFE.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, RPGLIFE.NS has a market cap of 43.6B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while RPGLIFE.NS trades at ₹2,636.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas RPGLIFE.NS's P/E ratio is 37.86. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check RPGLIFE.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GUFICBIO.BO has a market cap of 43.4B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GUFICBIO.BO trades at ₹432.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GUFICBIO.BO's P/E ratio is 67.64. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUFICBIO.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GUFICBIO.NS has a market cap of 43.3B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GUFICBIO.NS trades at ₹431.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GUFICBIO.NS's P/E ratio is 67.42. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUFICBIO.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GUJTHEM.NS has a market cap of 41.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GUJTHEM.NS trades at ₹381.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GUJTHEM.NS's P/E ratio is 88.65. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUJTHEM.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, GUJTHEM.BO has a market cap of 41.5B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while GUJTHEM.BO trades at ₹380.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas GUJTHEM.BO's P/E ratio is 29.35. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check GUJTHEM.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AARTIDRUGS.BO has a market cap of 38.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AARTIDRUGS.BO trades at ₹417.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AARTIDRUGS.BO's P/E ratio is 19.66. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIDRUGS.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, AARTIDRUGS.NS has a market cap of 38.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while AARTIDRUGS.NS trades at ₹417.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas AARTIDRUGS.NS's P/E ratio is 19.64. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.BO is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check AARTIDRUGS.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, UNICHEMLAB.BO has a market cap of 37.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while UNICHEMLAB.BO trades at ₹525.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas UNICHEMLAB.BO's P/E ratio is 14.64. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check UNICHEMLAB.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, UNICHEMLAB.NS has a market cap of 37B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while UNICHEMLAB.NS trades at ₹526.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas UNICHEMLAB.NS's P/E ratio is 14.65. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check UNICHEMLAB.NS's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, NOVARTIND.BO has a market cap of 35.1B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while NOVARTIND.BO trades at ₹1,423.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas NOVARTIND.BO's P/E ratio is 37.04. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NOVARTIND.BO's competition here

NATCO Pharma Limited (BSE: NATCOPHARM.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.BO stands at 158B. In comparison, NOVARTIND.NS has a market cap of 35B. Regarding current trading prices, NATCOPHARM.BO is priced at ₹882.50 on the BSE, while NOVARTIND.NS trades at ₹1,418.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.BO currently has a P/E ratio of 13.81, whereas NOVARTIND.NS's P/E ratio is 36.92. In terms of profitability, NATCOPHARM.BO's ROE is +0.13%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.BO is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.BO.Check NOVARTIND.NS's competition here